Thanks, Raphaël. So, just historically, the Company is not one that’s regularly engaged in hedging, preferring to realize the prices over the cycle, that delivers the most to shareholders. But we did, to your point, with our increased leverage, take on an oil hedge in 2020 that had a collar in 2020, but then it also had a call provision in 2021. So, the only thing remaining from that oil hedge is the call provision in 2021. We have put in place, as the slide deck shows, slide 20, natural gas hedges for 530 million standard cubic per day as of 12/31 with a value between $2.50 and $3.64 on a costless basis, similar to a costless basis we had on the hedge on oil last year. There’s no extending call option though on the gas side. We continue to evaluate additional hedges, particularly on the oil side on a regular basis. We evaluate the cost of doing so versus not doing so. As you can imagine, we do a pure put. It’s still fairly expensive, despite the improvement in price, and a costless type collar hedge is going to require both the cap in the current year in addition to the one we have hanging others today last year’s hedge, extending one into 2022. And so, when we look at the -- we moved the debt maturities down quite a bit in the near term, which is somewhat of a hedge against downturns in the business in the near term. We also know that shareholders appreciate our heavy exposure, leverage to oil price. And so, we have not put something in place as of now, but we’re going to kind of continue to evaluate them and see if they’re going to be constructive in the future.
Raphaël DuBois: That’s very helpful. Thank you. My second question is, have you quantified, if any, one-off cost for restarting your wells in Texas after the cold wave? And same question about your clinical division. Did you quantify any financial implications of the cold wave for this division?